Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CanSinoBIO and AstraZeneca Form mRNA Vaccine Collaboration

publication date: Aug 9, 2023

Tianjin CanSino Biologics, a vaccine company, extended its research alliance with AstraZeneca, agreeing to provide contract development and manufacturing services for AstraZeneca’s messenger RNA (mRNA) vaccine program. CanSino, which said it would manufacture and supply unspecified mRNA products to AstraZeneca, has an mRNA candidate that has completed China Phase II trials for COVID. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. In November 2022, the two companies announced they were collaborating to bring rare disease therapies to the China market. Financial details of the latest agreement were not disclosed. More details....

Stock Symbols:  (SHA: 688185; HK: 6185) (NYSE: ASN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital